Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2017 /
Long term follow up on the ZUMA-1 trial for nHL

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.12.17
Views: 1998

Dr Sattva Neelapu - MD Anderson Center, Houston, USA

Dr Neelapu speaks with ecancer at the 2017 ASH annual meeting about the long term follow up of the ZUMA-1 trial, looking at axicabtagene ciloleucel in patients with refractory aggressive non-Hodgkin lymphoma. He highlights that axicabtagene ciloleucel demonstrated significant clinical benefit with manageable adverse events in patients with no curative treatment options.

Read the news story or watch the press conference for more info.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation